
ESLA Stock Forecast & Price Target
ESLA Analyst Ratings
Bulls say
Estrella Immunopharma Inc has recently completed an $8 million financing and advanced EB103 into the Phase II portion of its ongoing Phase I/II study, which significantly strengthens its clinical and financial position. The STARLIGHT-1 trial has received an independent recommendation to proceed into Phase II, marking a critical milestone that supports operational momentum and broadens patient access as they gather more safety and efficacy data. Additionally, Estrella's innovative ARTEMIS platform is poised to unlock new market opportunities in both B-cell malignancies and solid tumors, positioning the company favorably in the rapidly evolving field of immunotherapy.
Bears say
The negative outlook on Estrella Immunopharma's stock is primarily driven by concerns regarding potential dilution following indications that management will discuss broader strategic priorities, including pipeline development and partnerships at the upcoming shareholders meeting. The downward adjustment in target price from $16.00 to $8.00 reflects a conservative stance in light of evolving assumptions around the company's financial outlook. Furthermore, the company faces competitive challenges with its therapies targeting relapsed/refractory B-cell Non-Hodgkin's Lymphomas, which could impede its growth in a rapidly evolving market.
This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
ESLA Analyst Forecast & Price Prediction
Start investing in ESLA
Order type
Buy in
Order amount
Est. shares
0 shares